fbpx
Thursday, April 25, 2024

New hope for pancreatitis treatment

Hudson Institute researchers in Victoria have identified a new pancreatitis treatment target, giving hope to sufferers of the disease worldwide.

Pancreatitis is a serious inflammatory gastrointestinal disorder which can lead to severe conditions, with as many as 20% of patients going on to experience multiple organ failure.

But despite its prevalence and impact, there are no specific and effective therapies to treat or prevent pancreatitis.

Now researchers have identified a key enzyme called ADAM17, which acts as a central molecular switch that leads to pancreatic inflammation – giving them a starting point for the development of new drugs to potentially treat pancreatitis.

Hudson Institute researcher, Dr Mohamed Saad, explains that ADAM17 acts as a ‘scissor’ to cut off particular inflammatory proteins on the cell membranes.

“These released proteins then activate inflammatory processes that lead to the development of pancreatitis,” he said.

“This discovery paves the way for developing inhibitor drugs that target ADAM17 activity to potentially treat pancreatitis.

“Pancreatitis is a multifactorial inflammatory disorder and a leading cause for gastrointestinal disease-related hospitalization, which is associated with substantial morbidity, mortality, and economic burden,” Dr Saad said.

“Our research is the first to implicate ADAM17 in the pathogenesis of pancreatitis, and to demonstrate the anti-inflammatory activities of an ADAM17 inhibitor; that gives us hope that we have found the key to new, effective treatments for this condition.”

This research was published in the journal Proceedings of the National Academy of Sciences (PNAS).

The research is being funded by NHMRC, the Victorian Government, and Cancer Council Victoria

Latest Articles